425: Avere Therapeutics Secures $500M Private Placement for IL-23 Therapy

Avere Therapeutics announces a $500 million private placement to advance its oral IL-23 therapy AVR-001, alongside a pending merger with NextCure, aiming to fully fund operations into 2029.

Summary

• Avere Therapeutics has secured a $500 million private placement, adding to a previously announced $320 million investment, to fund the development of its lead drug candidate, AVR-001, an oral IL-23 receptor antagonist.
• This financing, combined with the pending merger with NextCure, Inc., is expected to fully fund Avere's operating plan through 2029.
• The combined company will operate as Avere Therapeutics, Inc. and is expected to trade on Nasdaq under the ticker symbol AVRX.
• AVR-001 has demonstrated a half-life of approximately 100 hours, supporting once-weekly dosing, and has shown encouraging Phase 1 clinical proof-of-concept data in psoriasis, including meaningful improvements in PASI scores and key biomarkers.
• The company plans to advance AVR-001 in psoriasis and potentially expand into ulcerative colitis, Crohn's disease, and psoriatic arthritis.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive development, driven by significant new funding and promising clinical data for a key drug candidate, positioning the combined entity for substantial growth.

Positives

• Significant capital infusion of $500 million, in addition to $320 million previously announced, providing substantial financial runway.
• Expected to fully fund Avere's operating plan into 2029, reducing near-term financing concerns.
• Promising Phase 1 clinical data for AVR-001 showing a half-life supporting once-weekly dosing and encouraging efficacy signals in psoriasis.
• AVR-001's potential for a convenient, once-weekly oral administration compared to existing injectable or daily oral therapies.
• Experienced management team with a track record of successful drug development and company building.
• Strategic merger with NextCure to create a combined entity expected to trade on Nasdaq under the ticker AVRX.
• Potential to address large and growing markets for inflammatory diseases, including psoriasis and inflammatory bowel diseases.

Negatives

• The filing contains numerous forward-looking statements and disclaimers, indicating inherent uncertainties in drug development and market success.
• AVR-001 is still in early-stage development (Phase 1 data presented), and future clinical trials may yield unfavorable results or encounter safety issues.
• The IL-23 therapeutic landscape is competitive, with potential for superior or more cost-effective therapies from competitors.
• The company is dependent on an in-licensed program from Hansoh Pharma, with associated milestone and royalty obligations.
• Cross-trial comparisons of AVR-001's efficacy to Icotyde are noted as not being head-to-head and having differing trial designs and patient populations.

Risks

• The risk that the proposed merger and financings may not be completed on the anticipated timeline or at all.
• Failure to satisfy closing conditions for the merger, including obtaining necessary stockholder approvals.
• Risks related to the clinical development of AVR-001, including potential delays, unfavorable clinical results, safety or tolerability issues, or failure to obtain regulatory approval.
• Uncertainties regarding the capabilities and potential of Avere's pipeline programs.
• Market, macroeconomic, or other conditions that could adversely affect the combined company's cash runway or ability to raise additional capital.
• Risks related to the integration of the two companies and the management of a newly public company.
• The highly competitive nature of the IL-23-driven inflammatory disease therapeutic landscape.
• Risks related to the company's intellectual property, including potential infringement claims by third parties and the scope and enforceability of its rights.

Future Outlook

The combined company, operating as Avere Therapeutics, Inc., is expected to be fully funded into 2029, allowing for the continued development of AVR-001 through key clinical milestones, including Phase 2b studies in psoriasis and ulcerative colitis. The company anticipates advancing AVR-001 in psoriasis and potentially expanding into other IL-23 driven inflammatory diseases.

Management Comments

• "Icotyde has the potential to be one of our largest products ever."
• "Patients would rather take weekly than daily pill for more convenience."
• "Once-weekly dosing would lead to a huge improvement in patient compliance."
• "Would be a huge improvement to have once a week dosing to reduce the daily thoughts of psoriasis management."
• "Prescribers anticipate introduction of IL-23RA orals to increase market share >2x; Once available, a QW option likely to take majority of the oral market."
• "IL-23R: one of the most effective and safe targets in PsO."
• "Need exists for safe, highly effective oral therapies."

Industry Context

StockSavvy.ai notes that the announcement places Avere Therapeutics at the forefront of developing next-generation oral therapies for inflammatory diseases, particularly leveraging the validated IL-23 pathway. The significant capital raise and promising early data for AVR-001 position it to compete in a market currently dominated by injectables and facing evolving oral treatment options like Icotyde.

Comparison to Industry Standards

• AVR-001's Phase 1 data shows absolute percentage changes in PASI scores at Week 4 of -44% (all cohorts), -46% (QW cohorts), and -41% (QD cohorts), which are comparable to Icotyde's reported -44% in Phase 3 studies.
• At Week 8, AVR-001 showed absolute percentage changes in PASI scores of -70% (all cohorts), -68% (QW cohorts), and -72% (QD cohorts), compared to Icotyde's -66%.
• PASI 75 response rates at Week 4 for AVR-001 were 11% (all cohorts), 15% (QW cohorts), and 6% (QD cohorts), similar to Icotyde's 14% in Phase 3.
• At Week 8, AVR-001's PASI 75 response rates were 57% (all cohorts), 59% (QW cohorts), and 53% (QD cohorts), compared to Icotyde's 47%.
• Biomarker data (IL-17A and hBD-2) for AVR-001 at Week 4 showed Log2 factor changes of -0.8 (QW cohorts) and -1.8 (all cohorts) for IL-17A, and -2.4 (QW cohorts) and -2.7 (all cohorts) for hBD-2, which are consistent with Icotyde's reported changes.
• Icotyde, a QD oral IL-23RA, achieved clinical response rates of 54.7% (100mg QD) to 63.5% (400mg QD) in a Phase 2b ulcerative colitis study, with clinical remission rates between 21.9% and 30.2%. AVR-001 aims to achieve similar efficacy in IBD.

Stakeholder Impact

• Shareholders of NextCure will participate in the combined company, with their ownership percentage subject to adjustments based on NextCure's net cash at closing.
• Avere's existing investors are participating in the new private placement, reinforcing their commitment.
• Future patients suffering from inflammatory diseases like psoriasis and IBD may benefit from a more convenient and potentially effective oral treatment option (AVR-001).
• The successful development and commercialization of AVR-001 could lead to significant value creation for all stakeholders.

Next Steps

• Complete the merger with NextCure, Inc.
• Begin Phase 2b studies for AVR-001 in psoriasis.
• Initiate Phase 2b studies for AVR-001 in ulcerative colitis.
• Achieve China Phase 2b psoriasis readout (1H 2027).
• Achieve Phase 2b psoriasis readout (1H 2028).
• Initiate Phase 3 psoriasis studies (2028).

Key Dates

Recommendation

The significant capital raise and promising early-stage data for AVR-001 are positive indicators. However, the company is still pre-commercial, the merger is pending, and substantial clinical and regulatory hurdles remain. While the outlook is strong, a 'hold' recommendation reflects the inherent risks and the need for further de-risking through clinical trial progression and successful merger completion.

Keywords

Avere Therapeutics, NextCure, AVR-001, IL-23, Psoriasis, Inflammatory Diseases, Biotechnology, Merger